These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 19910903)

  • 1. Diagnostic value of FDG PET/CT imaging.
    Pace L; Nicolai E; Klain M; Salvatore M
    Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):503-12. PubMed ID: 19910903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging in endocrinology: 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up.
    Salvatori M; Biondi B; Rufini V
    Eur J Endocrinol; 2015 Sep; 173(3):R115-30. PubMed ID: 25947140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
    Lind P; Kohlfürst S
    Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis.
    Dong MJ; Liu ZF; Zhao K; Ruan LX; Wang GL; Yang SY; Sun F; Luo XG
    Nucl Med Commun; 2009 Aug; 30(8):639-50. PubMed ID: 19512954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.
    Dahele M; Ung YC; Ehrlich L; Silverberg J; Balogh J; Wong CS
    J Otolaryngol Head Neck Surg; 2008 Oct; 37(5):712-7. PubMed ID: 19128681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level.
    Bertagna F; Bosio G; Biasiotto G; Rodella C; Puta E; Gabanelli S; Lucchini S; Merli G; Savelli G; Giubbini R; Rosenbaum J; Alavi A
    Clin Nucl Med; 2009 Nov; 34(11):756-61. PubMed ID: 19851169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer.
    Nanni C; Rubello D; Fanti S; Farsad M; Ambrosini V; Rampin L; Banti E; Carpi A; Muzzio P; Franchi R
    Biomed Pharmacother; 2006 Sep; 60(8):409-13. PubMed ID: 16891093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients.
    Pryma DA; Schöder H; Gönen M; Robbins RJ; Larson SM; Yeung HW
    J Nucl Med; 2006 Aug; 47(8):1260-6. PubMed ID: 16883003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is it practical and cost effective to detect differentiated thyroid carcinoma metastases by (18)F-FDG PET/CT, by (18)F-FDG SPET/CT or by (131)I SPET/CT?
    He X; Wang X; Yu J; Ma C
    Hell J Nucl Med; 2015; 18(1):2-4. PubMed ID: 25679071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin.
    Kim SJ; Lee TH; Kim IJ; Kim YK
    Eur J Radiol; 2009 Apr; 70(1):17-24. PubMed ID: 18207685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma.
    Mirallié E; Guillan T; Bridji B; Resche I; Rousseau C; Ansquer C; Bodet-Milin C; Curtet C; Carnaille B; Murat A; Charbonnel B; Kraeber-Bodéré F
    Surgery; 2007 Dec; 142(6):952-8; discussion 952-8. PubMed ID: 18063081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. F-18 FDG PET/CT in the management of thyroid cancer.
    Iagaru A; Kalinyak JE; McDougall IR
    Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of positron emission tomography with [(18)F]FDG and [(68)Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data.
    Middendorp M; Selkinski I; Happel C; Kranert WT; Grünwald F
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):76-83. PubMed ID: 20168289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer.
    Esteva D; Muros MA; Llamas-Elvira JM; Jiménez Alonso J; Villar JM; López de la Torre M; Muros T
    Ann Surg Oncol; 2009 Jul; 16(7):2006-13. PubMed ID: 19415387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complementary role of 18F-fluorodeoxyglucose positron emission tomography and 131I scan in the follow-up of post-therapy differentiated thyroid cancer.
    Hsu CH; Liu RS; Wu CH; Chen SM; Shih LS
    J Formos Med Assoc; 2002 Jul; 101(7):459-67. PubMed ID: 12353337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning.
    Robbins RJ; Wan Q; Grewal RK; Reibke R; Gonen M; Strauss HW; Tuttle RM; Drucker W; Larson SM
    J Clin Endocrinol Metab; 2006 Feb; 91(2):498-505. PubMed ID: 16303836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of F-18-fluorodeoxyglucose positron emission tomography in the postoperative evaluation of differentiated thyroid cancer.
    Alzahrani AS; Abouzied ME; Salam SA; Mohamed G; Rifai A; Al Sugair A; Amin T
    Eur J Endocrinol; 2008 May; 158(5):683-9. PubMed ID: 18426827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.